Interferon beta (IFNβ) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFNβ has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFNβ, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.

45 μL of iLite^? IFN beta 1a NAb positive control diluted in RPMI 1640 with 10% heat inactivated fetal bovine serum (FBS) and 1% Penicillin Streptomycin.